Advertisement

Strategies to eliminate cancer stem cells: Clinical implications

      Abstract

      Over the past two decades, major advances in our understanding of cancer have translated into only modest increments in survival for the majority of cancer patients. Recent data suggesting cancers arise from rare self-renewing stem cells that are biologically distinct from their more numerous differentiated progeny may explain this paradox. Current anticancer therapies have been developed to decrease the bulk of the tumour mass (i.e. the differentiated cancer cells). Although treatments directed against the bulk of the cancer may produce dramatic responses, they are unlikely to result in long-term remissions if the rare cancer stem cells are also not targeted. Conversely, treatments that selectively attack cancer stem cells will not immediately eliminate the differentiated cancer cells, and might therefore be prematurely abandoned if clinical activity is judged solely by traditional response criteria that reflect changes in the bulk of the tumour. Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weir H.K.
        • Thun M.J.
        • Hankey B.F.
        • et al.
        Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control.
        J Natl Cancer Inst. 2003; 95: 1276-1299
        • Pileri S.A.
        • Zinzani P.L.
        • Went P.
        • Pileri Jr., A.
        • Bendandi M.
        Indolent lymphoma: the pathologist’s viewpoint.
        Ann Oncol. 2004; 15: 12-18
        • Abratt R.P.
        • Brune D.
        • Dimopoulos M.A.
        • et al.
        Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
        Ann Oncol. 2004; 15: 1613-1621
        • Trump D.
        • Lau Y.K.
        Chemotherapy of prostate cancer: present and future.
        Curr Urol Rep. 2003; 4: 229-232
        • Rocha Lima C.M.
        • Green M.R.
        • Rotche R.
        • et al.
        Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
        J Clin Oncol. 2004; 22: 3776-3783
        • Chung C.T.
        • Carlson R.W.
        Goals and objectives in the management of metastatic breast cancer.
        Oncologist. 2003; 8: 514-520
        • Fossella F.
        • Pereira J.R.
        • von Pawel J.
        • et al.
        Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
        J Clin Oncol. 2003; 21: 3016-3024
        • Petrylak D.P.
        • Tangen C.M.
        • Hussain M.H.
        • et al.
        Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
        New Engl J Med. 2004; 351: 1513-1520
        • Burris III, H.A.
        • Moore M.J.
        • Andersen J.
        • et al.
        Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
        J Clin Oncol. 1997; 15: 2403-2413
        • Jones R.J.
        • Matsui W.H.
        • Smith B.D.
        Cancer stem cells: are we missing the target?.
        J Natl Cancer Inst. 2004; 96: 583-585
        • Ben-Neriah Y.
        • Daley G.Q.
        • Mes-Masson A.-.M.
        • Witte O.N.
        • Baltimore D.
        The chronic myelogenous leukemia – Specific P210 protein is the product of the bcr–abl hybrid gene.
        Science. 1986; 233: 212-214
        • Daley G.Q.
        • VanEtten R.A.
        • Baltimore D.
        Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
        Science. 1990; 247: 824-830
        • Kelliher M.A.
        • McLaughlin J.
        • Witte O.N.
        • Rosenberg N.
        Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
        Proc Natl Acad Sci USA. 1990; 87: 6649-6653
        • Buchdunger E.
        • Zimmermann J.
        • Mett H.
        • et al.
        Inhibition of the Abl protein–tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
        Cancer Res. 1996; 56: 100-104
        • Druker B.J.
        • Tamura S.
        • Buchdunger E.
        • et al.
        Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells.
        Nat Med. 1996; 2: 561-566
        • Druker B.J.
        • Sawyers C.L.
        • Kantarjian H.
        • et al.
        Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
        New Engl J Med. 2001; 344: 1038-1042
        • Kantarjian H.
        • Sawyers C.
        • Hochhaus A.
        • et al.
        Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
        New Engl J Med. 2002; 346: 645-652
        • Talpaz M.
        • Silver R.T.
        • Druker B.J.
        • et al.
        Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
        Blood. 2002; 99: 1928-1937
        • O’Brien S.G.
        • Guilhot F.
        • Larson R.A.
        • et al.
        Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
        New Engl J Med. 2003; 348: 994-1004
        • NCCN
        Chronic myelogenous leukemia clinical practice guidelines in oncology.
        J Natl Comprehensive Cancer Network. 2003; 1: 482-500
        • Cortes J.
        • O’Brien S.
        • Kantarjian H.
        Discontinuation of imatinib therapy after achieving a molecular response.
        Blood. 2004; 104: 2204-2205
        • Mauro M.J.
        • Druker B.J.
        • Kuyl J.
        • Kurilik G.
        • Maziarz R.T.
        Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR–ABL.
        Proc ASCO. 2003; 22: 569
        • Gorre M.E.
        • Mohammed M.
        • Ellwood K.
        • et al.
        Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification.
        Science. 2001; 293: 876-880
        • Hochhaus A.
        • Kreil S.
        • Corbin A.S.
        • et al.
        Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
        Leukemia. 2002; 16: 2190-2196
        • Bedi A.
        • Zehnbauer B.A.
        • Collector M.I.
        • et al.
        BCR–ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
        Blood. 1993; 81: 2898-2902
        • Holtz M.S.
        • Slovak M.L.
        • Zhang F.
        • Sawyers C.L.
        • Forman S.J.
        • Bhatia R.
        Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
        Blood. 2002; 99: 3792-3800
        • Angstreich G.R.
        • Matsui W.
        • Huff C.A.
        • et al.
        Effects of imatinib and interferon on primitive chronic myeloid leukemia progenitors.
        Brit J Haematol. 2005; 130: 373-381
        • Graham S.M.
        • Jorgensen H.G.
        • Allan E.
        • et al.
        Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
        Blood. 2002; 99: 319-325
        • Jones R.J.
        Leukemic stem cells – where have they gone wrong?.
        Blood. 2001; 97: 3681-3682
        • Raaijmakers M.H.
        • van Emst L.
        • De Witte T.
        • Mensink E.
        • Raymakers R.A.
        Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction.
        Exp Hematol. 2002; 30: 481-487
        • Bunting K.D.
        ABC transporters as phenotypic markers and functional regulators of stem cells.
        Stem Cells. 2002; 20: 11-20
        • Burger H.
        • van Tol H.
        • Boersma A.W.
        • et al.
        Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
        Blood. 2004; 104: 2940-2942
        • Mahon F.X.
        • Belloc F.
        • Lagarde V.
        • et al.
        MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
        Blood. 2003; 101: 2368-2373
        • Jamieson C.H.
        • Ailles L.E.
        • Dylla S.J.
        • et al.
        Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
        New Engl J Med. 2004; 351: 657-667
        • Keating A.
        • Wang X.H.
        • Laraya P.
        Variable transcription of BCR–ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia.
        Blood. 1994; 83: 1744-1749
        • Holyoake T.
        • Jiang X.
        • Eaves C.
        • Eaves A.
        Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.
        Blood. 1999; 94: 2056-2064
        • Jiang G.
        • Yang F.
        • Li M.
        • et al.
        Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR–ABL genes.
        Cancer Biol Ther. 2003; 2: 103-108
        • Bonifazi F.
        • de Vivo A.
        • Rosti G.
        • et al.
        Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
        Blood. 2001; 98: 3074-3081
        • Pierce A.
        • Smith D.L.
        • Jakobsen L.V.
        • Whetton A.D.
        • Spooncer E.
        The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells.
        Hematol J. 2001; 2: 257-264
        • Matsui W.
        • Huff C.A.
        • Wang Q.
        • et al.
        Characterization of clonogenic multiple myeloma cells.
        Blood. 2004; 103: 2332-2336
        • Matsui W.H.
        • Huff C.A.
        • Wang Q.
        • Barber J.P.
        • Smith B.D.
        • Jones R.J.
        Multiple myeloma stem cells and plasma cells display distinct drug sensitivities.
        Blood. 2004; 104: 679a
        • Matsui W.
        • Huff C.A.
        • Wang Q.
        • et al.
        Characterization of clonogenic multiple myeloma cells.
        Blood. 2004; 103: 2332-2336
        • Treon S.P.
        • Pilarski L.M.
        • Belch A.R.
        • et al.
        CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
        J Immunother. 2002; 25: 72-81
        • Lapidot T.
        • Sirard C.
        • Vormoor J.
        • et al.
        A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
        Nature. 1994; 367: 645-648
        • Wittebol S.
        • Raymakers R.
        • van de L.L.
        • Mensink E.
        • De Witte T.
        In AML t (8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction.
        Leukemia. 1998; 12: 1782-1788
        • Blair A.
        • Hogge D.E.
        • Sutherland H.J.
        Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34 (+)/CD71 (−)/HLA–DR–.
        Blood. 1998; 92: 4325-4335
        • Uckun F.M.
        • Messinger Y.
        • Chen C.L.
        • et al.
        Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
        Clin Cancer Res. 1999; 5: 3906-3913
        • Szatrowski T.P.
        • Dodge R.K.
        • Reynolds C.
        • et al.
        Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
        Cancer. 2003; 97: 1471-1480
        • George A.A.
        • Franklin J.
        • Kerkof K.
        • et al.
        Detection of leukemic cells in the CD34 (+)CD38 (−) bone marrow progenitor population in children with acute lymphoblastic leukemia.
        Blood. 2001; 97: 3925-3930
        • Nilsson L.
        • Astrand-Grundstrom I.
        • Anderson K.
        • et al.
        Involvement and functional impairment of the CD34 (+)CD38 (−)Thy-1 (+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
        Blood. 2002; 100: 259-267
        • Al Hajj M.
        • Wicha M.S.
        • Benito-Hernandez A.
        • Morrison S.J.
        • Clarke M.F.
        Prospective identification of tumorigenic breast cancer cells.
        Proc Natl Acad Sci USA. 2003; 100: 3983-3988
        • Singh S.K.
        • Clarke I.D.
        • Terasaki M.
        • et al.
        Identification of a cancer stem cell in human brain tumors.
        Cancer Res. 2003; 63: 5821-5828
        • Hemmati H.D.
        • Nakano I.
        • Lazareff J.A.
        • et al.
        Cancerous stem cells can arise from pediatric brain tumors.
        Proc Natl Acad Sci USA. 2003; 100: 15178-15183
        • Kim C.F.
        • Jackson E.L.
        • Woolfenden A.E.
        • et al.
        Identification of bronchioalveolar stem cells in normal lung and lung cancer.
        Cell. 2005; 121: 823-835
        • Verfaillie C.M.
        • Miller W.J.
        • Boylan K.
        • McGlave P.B.
        Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
        Blood. 1992; 79: 1003-1010
        • Leemhuis T.
        • Leibowitz D.
        • Cox G.
        • et al.
        Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
        Blood. 1993; 81: 801-807